Info

🌱 來自: DCIS and LCIS

NSABP B-35

  1. Design: Randomized controlled trial.
  2. Number of patients: 3104 patients were entered and randomized, with follow-up information available on 3083 patients for OS and 3077 for all other disease-free endpoints.
  3. Patients characteristics: Not reported.
  4. Agents: Tamoxifen (T) and anastrozole (A), both aromatase inhibitors.
  5. Treatment line: Adjuvant therapy after surgery.
  6. Trial Name/NCT Number: Not reported.
  7. Comparison of two groups in a markdown table:
Group/OutcomeTamoxifenAnastrozole
10-year estimate for breast cancer-free interval (BCFI)89.1% (95% CI, 86.8-91.0)93.1% (95% CI, 91.5-94.5)
Hazard ratio (HR) for BCFI0.73 (95% CI, 0.56-0.96)Not reported
P value0.0234Not reported
10-year estimate for disease-free survival (DFS)77.9% (95% CI, 75.0-80.6)82.7% (95% CI, 80.4-84.7)
HR for DFS0.89 (95% CI, 0.75-1.07)Not reported
P value0.21Not reported
10-year estimate for overall survival (OS)92.1% (95% CI, 90.1-93.7)92.5% (95% CI, 90.8-93.9)
HR for OS1.11 (95% CI, 0.83-1.48)Not reported
P value0.48Not reported
Deaths due to breast cancer85
Cases of invasive breast cancer6943
HR for contralateral breast cancers0.64 (95% CI, 0.43-0.96)Not reported
P value0.0322Not reported

Note: Specific patient characteristics, such as age or menopausal status, are not provided. The trial name and NCT number are not reported.